Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib
Work
Year: 2014
Type: article
Abstract: Ibrutinib is an irreversible inhibitor of Bruton's tyrosine kinase (BTK) and is effective in chronic lymphocytic leukemia (CLL). Resistance to irreversible kinase inhibitors and resistance associated ... more
Source: New England Journal of Medicine
Authors Jennifer A. Woyach, Richard R. Furman, Ta-Ming Liu, Hatice Gülçin Özer, Marc Zapatka +20 more
Institutions Cornell University, German Cancer Research Center, Heidelberg University, Pharmacyclics (United States), Janssen (Belgium) +4 more
Cites: 34
Cited by: 1,153
Related to: 10
FWCI: 69.01
Citation percentile (by year/subfield): 99.99
Subfield: Genetics
Field: Medicine
Domain: Health Sciences
Sustainable Development Goal Good health and well-being
Open Access status: bronze